Abstract

Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Do Existing Definitions Identify Subgroup Phenotypes or Reflect the Natural History of Heart Failure With Preserved Ejection Fraction?
Walter J Paulus ... Michele Senni
Circulation | VOL. 140
Walter J Paulus, et. al.Walter J Paulus ... Michele Senni
29 Jul 2019
New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment.
Michael R Zile ... Dirk L Brutsaert
Circulation | VOL. 105
Michael R Zile, et. al.Michael R Zile ... Dirk L Brutsaert
26 Mar 2002
Could a Low-Dose Diuretic Polypill Improve Outcomes in Heart Failure With Preserved Ejection Fraction?
Sadiya S Khan ... Sanjiv J Shah
Circulation: Heart Failure | VOL. 14
Sadiya S Khan, et. al.Sadiya S Khan ... Sanjiv J Shah
01 Mar 2021
Ventricular remodelling: an equal-opportunity prognosticator.
Marvin A Konstam
European journal of heart failure | VOL. 22
Marvin A KonstamMarvin A Konstam
01 Dec 2020
View more papers

More From: European journal of heart failure

Paper Title
Journal
Date
Author
Sodium-glucose cotransporter 2 inhibitors in acute and chronic coronary syndrome with and without heart failure.
Eugenia Cisneros-Barroso ... Xavier Rossello
European journal of heart failure | VOL. -
Eugenia Cisneros-Barroso, et. al.Eugenia Cisneros-Barroso ... Xavier Rossello
29 May 2024
Impact of malnutrition in patients with severe heart failure.
Matteo Pagnesi ... Marco Metra
European journal of heart failure | VOL. -
Matteo Pagnesi, et. al.Matteo Pagnesi ... Marco Metra
29 May 2024
Is the optimal dose of heart failure medical therapy different in women and men?
Maria A Pabon ... Carolyn S P Lam
European journal of heart failure | VOL. -
Maria A Pabon, et. al.Maria A Pabon ... Carolyn S P Lam
27 May 2024
Sacubitril/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM).
Lazar Velicki ...
European journal of heart failure | VOL. -
Lazar Velicki, et. al.Lazar Velicki ...
27 May 2024
View more papers